Centre François Baclesse Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2018
NCT03752216
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Centre François Baclesse 3, avenue du Général Harris 14076 CAEN

Active Ingredients

Drugs in Phase 4 Trials (1)

niraparib (zejula) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 4)

Ovarian Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1